Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the ...

On an adjusted basis, Regeneron earned $8.22 per share in the first quarter, below the average analyst estimate of $8.82, ...

Q1 2025 Management View CEO Leonard Schleifer highlighted mixed performance in Q1 2025, with challenges in the retinal ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Regeneron (REGN) stock drops as the company's Q1 2025 results miss forecasts amid disappointing sales from its blockbuster ...

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron’s ability to develop blockbuster drugs. Regeneron appears ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.